Literature DB >> 11557198

Preferences for quality of life or survival expressed by patients with heart failure.

E F Lewis1, P A Johnson, W Johnson, C Collins, L Griffin, L W Stevenson.   

Abstract

BACKGROUND: As many patients with heart failure develop symptoms limiting daily life, newer therapies may be found to improve functional status without concomitant survival benefit. As some of these therapies may actually increase mortality, it is increasingly relevant to assess patients' preferences for survival vs improvement in symptoms.
METHODS: We enrolled 99 patients with advanced heart failure (ejection fraction 24 +/- 10, duration 6 +/- 5 years). Each patient completed time trade-off and standard gamble instruments, Minnesota Living with Heart Failure questionnaires and visual analog scales for dyspnea and overall health. Jugular venous pressure was assessed in all patients and peak oxygen consumption was measured during bicycle exercise in 60 patients.
RESULTS: Strong polarity of preference toward either survival or quality of life was expressed by 60% of patients. There was good correlation between time trade-off and standard gamble utility scores (r = 0.64), and between preference and functional class (r = 0.60). Higher jugular venous pressure and lower peak oxygen consumption were associated with poorer utility scores (p <.05). Higher dyspnea scores and worse Living with Heart Failure scores were also associated with preference to trade time or take risks for better health.
CONCLUSIONS: These findings suggest that heart failure patients express meaningful preferences about quality vs length of life. High jugular venous pressure, low peak oxygen consumption and poor Living with Heart Failure scores were related to low utility scores. These cannot be assumed, however, to predict the intensity of individual preference to trade nothing or virtually everything for better health.

Entities:  

Mesh:

Year:  2001        PMID: 11557198     DOI: 10.1016/s1053-2498(01)00298-4

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  90 in total

Review 1.  Informed consent in cardiac resynchronization therapy: what should be said?

Authors:  Daniel B Kramer; Dan W Brock; Usha B Tedrow
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-09

Review 2.  Optimising outcomes in end-stage heart failure: differences in therapeutic responses between diverse ethnic groups.

Authors:  Shigetake Sasayama
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

3.  Heart Failure Exercise And Training Camp: effects of a multicomponent exercise training intervention in patients with heart failure.

Authors:  Bunny Pozehl; Kathleen Duncan; Melody Hertzog; Joseph F Norman
Journal:  Heart Lung       Date:  2010-07-03       Impact factor: 2.210

4.  Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer.

Authors:  Lindsay Hedden; Susan O'Reilly; Caroline Lohrisch; Stephen Chia; Caroline Speers; Laurel Kovacic; Suzanne Taylor; Stuart Peacock
Journal:  Oncologist       Date:  2012-02-02

Review 5.  Drug therapy optimization at the end of life.

Authors:  Alfonso J Cruz-Jentoft; Benoit Boland; Lourdes Rexach
Journal:  Drugs Aging       Date:  2012-06-01       Impact factor: 3.923

6.  How to define a poor outcome after transcatheter aortic valve replacement: conceptual framework and empirical observations from the placement of aortic transcatheter valve (PARTNER) trial.

Authors:  Suzanne V Arnold; John A Spertus; Yang Lei; Philip Green; Ajay J Kirtane; Samir Kapadia; Vinod H Thourani; Howard C Herrmann; Nirat Beohar; Alan Zajarias; Michael J Mack; Martin B Leon; David J Cohen
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2013-09-10

Review 7.  Assessment of quality of life in severe heart failure.

Authors:  Prashant Vaishnava; Eldrin F Lewis
Journal:  Curr Heart Fail Rep       Date:  2007-09

8.  Assessing patients' improvement in clinical trials.

Authors:  John Spertus
Journal:  BMJ       Date:  2008-05-21

9.  Health-related quality of life in unselected outpatients with heart failure across Spain in two different health care levels. Magnitude and determinants of impairment: the INCA study.

Authors:  Beatriz de Rivas; Gaietà Permanyer-Miralda; Carlos Brotons; Joaquín Aznar; Eduardo Sobreviela
Journal:  Qual Life Res       Date:  2008-10-15       Impact factor: 4.147

10.  Cost-effectiveness of cardiac resynchronization therapy in combination with an implantable cardioverter defibrillator (CRT-D) for the treatment of chronic heart failure from a German health care system perspective.

Authors:  Pamela Aidelsburger; Kristin Grabein; Volker Klauss; Jürgen Wasem
Journal:  Clin Res Cardiol       Date:  2007-10-25       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.